Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

IND in effect for Fulcrum's phase I study of FTX-6058 for sickle cell disease

Oct. 5, 2020

Roche opens enrollment in phase III studies of crovalimab for PNH

Oct. 2, 2020

Discovery of new potent, selective and orally bioavailable inhibitors of factor XI

Oct. 2, 2020

BCX-9930 shows clinical benefit as monotherapy in treatment-naive patients with PNH

Oct. 1, 2020

Enaroy approved in Japan for anemia associated with chronic kidney disease

Sep. 29, 2020

FDA approves Nucala for hypereosinophilic syndrome

Sep. 28, 2020

Phase I/IIa data published for BIVV-001 in patients with hemophilia A

Sep. 21, 2020

OD-66 restores hemoglobin levels in model of cancer-induced anemia

Sep. 15, 2020

Blood studies identify new trait-related variants

Sep. 10, 2020

Enrollment begins in phase I study of AG-946

Sep. 9, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...